24/7 Customer Support

Respiratory Syncytial Virus Market - Industry Dynamics, Market Size, and Opportunity Forecast to 2027

Global Respiratory Syncytial Virus Market, By Drug Type (Synagis, Virazole, Palivizumab, Riba Tab and Others), By Dosage Form (Oral, Injectable, Inhaler and Others), By Treatment Type (Immune Prophylaxis, Supportive Care and Antiviral Medications), By Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies and Clinics), By Region(North America, Europe, Asia Pacific, South America, Middle East & Africa), Competition, Forecast & Opportunities to 2027

  • Published On: 02-Aug-2021  |  Format: pdfpowerpointexcel  |  Report ID: AA0821085
    Delivery: 2 to 4 Hours
INFOGRAPHIC:
Respiratory Syncytial Virus Market

View Full Infographic

REPORT SCOPE

Market Size Value in 2021US$ 1,823.3 Mn
Expected Revenue in 2027US$ 4,202.6 Mn
Historic Data2017-2020
Base Year2021
Forecast Period2022-2027
UnitValue (USD Mn)
CAGR14.8% 
Segments coveredBy Drug Type, By Dosage Form, By Treatment Type, By Distribution Channel
Key Companies                                                                                                  AbbVie, Inc, AstraZeneca PLC, Atea Pharmaceuticals, Bausch Health Companies Inc., Celltrion Inc, Enanta Pharmaceuticals, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Johnson & Johnson's, mAbxience, Merck Co., Inc., Pfizer Inc., and Sanofi.
Customization ScopeGet your customized report as per your preference. Ask for customization

FREQUENTLY ASKED QUESTIONS

The Global Respiratory Syncytial Virus Market is expected to reach US$ 4,202.6 Million by 2027.

The current size of the Global Respiratory Syncytial Virus Market is US$ 1,669.5 Million.

High cost of technology and inaccessibility of diagnostic facilities are some factors hampering the growth of the market.

The Global Respiratory Syncytial Virus Market is expected to grow at a CAGR of 14.9% in terms of revenue in the forecasted period.

Increased disease prevalence and advent of targeted therapies are major drivers to the Global Respiratory Syncytial Virus Market.

North America is the largest shareholder in the market.

Injectable type of dosage holds the highest share in the Global Respiratory Syncytial Virus Market. 

Key players of the Global Respiratory Syncytial Virus Market are AstraZeneca PLC, Atea Pharmaceuticals, Bausch Health Companies Inc., Celltrion Inc., Enanta Pharmaceuticals, Inc and Others.

The report provides market size estimates for period of 2017-2027. Wherein, 2017-2019 is the historic period. 2020 is the base year, and 2021-2027 is the forecast period. In all, forecast is provided for a term of six years in the report.

Rising R&D expenditure in the healthcare sectors and increasing respiratory tract diseases among children and elderly are the trends to the Global Respiratory Syncytial Virus Market.

Based on distribution channel, the market is segmented into hospital pharmacies, dug stores, Retail pharmacies and clinics.